Health TrialsbyHealthPanel

Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults

ConditionsJuvenile Idiopathic ArthritisRheumatoid ArthritisPsoriatic ArthritisSystemic Lupus ErythematosusDiffuse Systemic SclerosisSeronegative Arthritis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2-50
SponsorUniversité Catholique de Louvain

About this trial

Population:

Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS).

Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.

These 5 cohorts will be subject to standardized clinical monitoring.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of juvenile idiopathic arthritis, rheumatoid arthritis and seronegative / psoriatic / undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis (ACR criteria).

Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.

Disqualifiers

Treated for > 3 months

> 50 years old

Trial population

Patients with juvenile idiopathic arthritis, rheumatoid arthritis and seronegative / psoriatic / undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

1,000 Participants
are grouped into 5 trial groups
Group A: juvenile idiopathic arthritis (JIA)
Group B: rheumatoid arthritis (RA)
Group C: diffuse systemic sclerosis (dSS)
Group D: seronegative arthritis (UA)
Group E: systemic lupus erythematosus (SLE)

Trial outcomes

Primary outcomes

1

Remission rate or absence of synovitis in Rheumatoid arthritis patients

Time frame
Through the entire study, during approximately 15 years

Secondary outcomes

Other outcomes

1

Remission rates improvement in Juvenile arthritis (JIA) patients

Time frame
Through the entire study, during approximately 15 years
2

Reduction in damage rate in Systemic Lupus Erythematosus patients

Time frame
Through the entire study, during approximately 15 years
3

Inclusion of at least 80% of the incident cases of diffuse Systemic sclerosis

Time frame
Through the entire study, during approximately 15 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Université Catholique de Louvain

Lead sponsor

Source ClinicalTrials.gov
Apply now